BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 55.35 -0.4 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.75 | 52 Week High | $108.96 | |||
| Open | $55.83 | 52 Week Low | $62.12 | |||
| Day High | $56.09 | P/E | N/A | |||
| Day Low | $55.05 | EPS | $-1.27 | |||
| Volume | 2,455,373 | |||||
